Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
Description: Asterias Biotherapeutics, Inc., a development stage biotechnology company, focuses on the development of therapeutic products to treat neurology, oncology, cardiology, metabolic diseases, ophthalmology, orthopedics, and blood and vascular diseases. It is also developing human embryonic stem cell programs, including cell lines and a Phase I clinical trial in patients with acute spinal cord injury; intellectual property related to its autologous cellular immunotherapy program, including a Phase I/II clinical trial of autologous immunotherapy in patients with acute myelogenous leukemia; and non-therapeutic applications of pluripotent stem cells, such as cellular assay products for use in drug development and toxicity screening. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is based in Menlo Park, California.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||3609.52%||Sales Growth - Q/Q||-26.23%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-20.54%||ROE||-27.98%||ROI|
|Current Ratio||2.62||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.27|
|Gross Margin||92.53%||Operating Margin||-946.27%||Net Profit Margin||-555.54%||Dividend Payout Ratio|
|Cash From Financing Activities||5.36 M||Cash From Investing Activities||-310 K||Cash From Operating Activities||-700 K||Gross Profit||730 K|
|Net Profit||-2.97 M||Operating Profit||-4.54 M||Total Assets||52.5 M||Total Current Assets||27.36 M|
|Total Current Liabilities||10.45 M||Total Debt||560 K||Total Liabilities||13.97 M||Total Revenue||780 K|
|High 52 week||2.25||Low 52 week||0.56||Last close||0.94||Last change||1.24%|
|RSI||50.2||Average true range||0.05||Beta||1.12||Volume||162.01 K|
|Simple moving average 20 days||3.52%||Simple moving average 50 days||18.78%||Simple moving average 200 days||-26.14%|
|Performance Week||5.79%||Performance Month||28.62%||Performance Quart||-25.87%||Performance Half||-44.62%|
|Performance Year||-57.2%||Performance Year-to-date||51.85%||Volatility daily||7.88%||Volatility weekly||17.63%|
|Volatility monthly||36.13%||Volatility yearly||125.14%||Relative Volume||241%||Average Volume||195.2 K|
|New High||New Low|
2019-02-08 09:51:02 | What Makes Asterias Biotherapeutics AST a New Buy Stock
2018-12-18 17:32:10 | Achillion Reports Positive Interim Data on Factor D Inhibitors
2018-11-23 08:20:00 | New Research Coverage Highlights Vulcan Materials, Cimpress N.V, Asterias Biotherapeutics, ElectraMeccanica Vehicles, Compugen, and China HGS Real Estate — Consolidated Revenues, Company Growth, and Expectations for 2018
2018-11-09 17:25:10 | Asterias Biotherapeutics AST Reports Q3 Loss, Tops Revenue Estimates
2018-11-09 16:17:28 | Asterias Biotherapeutics: 3Q Earnings Snapshot
2018-11-09 16:10:00 | Asterias Biotherapeutics Reports Third Quarter Results
2018-11-08 13:49:08 | Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Asterias Biotherapeutics, Inc. AST on Behalf of Stockholders and Encourages AST Investors to Contact the Firm
2018-11-08 12:00:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Asterias Biotherapeutics, Inc.
2018-11-08 06:30:00 | BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update
2018-11-02 07:00:00 | Asterias Biotherapeutics to Report Third Quarter 2018 Results on November 12, 2018
2018-10-23 09:32:33 | What Kind Of Shareholders Own Asterias Biotherapeutics Inc NYSEMKT:AST?
2018-10-01 07:00:00 | Asterias Biotherapeutics Announces Facilities and IP License Option Agreements
2018-09-17 15:32:20 | Healthcare Stocks: Is Now The Time To Buy Asterias Biotherapeutics Inc NYSEMKT:AST?
2018-08-30 08:46:12 | Are Options Traders Betting on a Big Move in Asterias Biotherapeutics AST Stock?
2018-08-09 17:50:09 | Asterias Biotherapeutics AST Reports Q2 Loss, Tops Revenue Estimates
2018-08-09 16:43:30 | Asterias Biotherapeutics: 2Q Earnings Snapshot
2018-08-09 15:00:00 | Asterias Biotherapeutics Inc Class A to Host Earnings Call
2018-07-26 07:00:00 | Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018
2018-07-17 08:56:01 | Benzinga Pro's 5 Stocks To Watch Today
2018-07-12 07:00:00 | Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Stroke IP; Second Pre-Clinical Collaboration Initiated to Test the Efficacy of AST-OPC1 for the Treatment of Stroke
2018-07-11 11:05:03 | Achillion's 3rd Factor D Inhibitor Enters Clinical Studies
2018-07-11 08:31:12 | VIVUS, Inc. VVUS Soars: Stock Adds 10.1% in Session
2018-07-11 05:14:09 | Asterias Biotherapeutics Sees Hammer Chart Pattern: Time to Buy?
2018-07-06 22:11:36 | Asiatravel.com Suspends Trading as Going Concern Risk Flagged
2018-06-26 08:34:29 | Does ASTARTA Holding NV’s WSE:AST -63.13% Earnings Drop Reflect A Longer Term Trend?
2018-05-26 09:41:16 | ASTARTA Holding NV. WSE:AST: Can It Deliver A Superior ROE To The Industry?
2018-05-09 19:54:21 | Asterias Biotherapeutics: 1Q Earnings Snapshot
2018-05-03 16:01:00 | Asterias Biotherapeutics to Report First Quarter 2018 Results on May 9, 2018
2018-05-03 08:52:12 | Are Options Traders Betting on a Big Move in Asterias Biotherapeutics AST Stock?